Prasugrel 5 mg 	Clopidogrel 75 mg	P2Y12 reaction unit (PRU) values at 30 days	10838	11016	At 30 days after randomization, the 5 mg prasugrel group had significantly lower PRU value compared with that of the 75 mg clopidogrel group (174.6±60.2 vs. 223.4±72.9, p=0.022),
Prasugrel 5 mg 	Clopidogrel 75 mg	P2Y12 reaction unit (PRU) values higher than 235	1485	1664	The rate of high on-treatment platelet reactivity (PRU >235) was significant lower in the 5 mg prasugrel group than that in the 75 mg clopidogrel group (15.0% vs. 56.5%, p=0.010).
Prasugrel 5 mg 	Prasugrel 10 mg	P2Y12 reaction unit (PRU) values at 30 days	1204	1484	The prasugrel (5 mg) group had a significantly lower PRU value compared with that of 75 mg clopidogrel (174.6±60.2 vs. 223.4±72.9, p=0.022) group at 30 days, whereas the 10 mg prasugrel group showed a lower PRU value (71.9±34.4) compared with that of the 5 mg prasugrel (p<0.001).
Prasugrel 5 mg 	Prasugrel 10 mg	P2Y12 reaction unit (PRU) values at 30 days	1370	1484	the 10 mg prasugrel group showed a lower PRU value (71.9±34.4) compared with that of the 5 mg prasugrel (p<0.001).
Clopidogrel 75 mg or prasugrel 5 mg 	Prasugrel 10 mg	P2Y12 reaction unit (PRU) values at baseline	1128	1203	No differences in baseline PRU values were observed among the three groups.
Prasugrel 5 mg 	Clopidogrel 75 mg	P2Y12 reaction unit (PRU) values at 30 days	1204	1360	The prasugrel (5 mg) group had a significantly lower PRU value compared with that of 75 mg clopidogrel (174.6±60.2 vs. 223.4±72.9, p=0.022) group at 30 days
Clopidogrel 75 mg or prasugrel 5 mg 	Prasugrel 10 mg	Life threatening bleeding events	12062	12220	Thrombolysis in Myocardial Infarction major bleeding or life threatening bleeding events did not occur during the study period in any of the treatment groups.
Clopidogrel 75 mg or prasugrel 5 mg 	Prasugrel 10 mg	Life threatening bleeding events	12098	12219	n major bleeding or life threatening bleeding events did not occur during the study period in any of the treatment groups
